HLTH:LSE:LSE-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 234.8

Change

+2.18 (+0.93)%

Market Cap

USD 0.69B

Volume

1.39K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+3.46 (+1.26%)

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

+0.55 (+0.82%)

USD 292,109.19B
0R1O:LSE Amazon.com Inc.

+8.00 (+4.26%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.33 (+0.27%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.04 (+0.26%)

USD 553.83B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.07 (+0.40%)

USD 553.83B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+1.25 (+0.06%)

USD 321.87B
0QZK:LSE Coca-Cola Co.

-0.05 (-0.08%)

USD 266.08B
0QZO:LSE 0QZO

+0.20 (+0.20%)

USD 258.54B

ETFs Containing HLTH:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.73% 91% A- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.73% 91% A- 84% B
Trailing 12 Months  
Capital Gain 18.92% 72% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.92% 71% C- 70% C-
Trailing 5 Years  
Capital Gain 70.49% 83% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.49% 81% B- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 8.30% 63% D 67% D+
Dividend Return 8.30% 62% D 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.11% 76% C+ 86% B+
Risk Adjusted Return 102.33% 98% N/A 98% N/A
Market Capitalization 0.69B 74% C 57% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike